Rosenberg Ellen 4

4 · AMICUS THERAPEUTICS, INC. · Filed Nov 26, 2025

Form 4

Period: 2025-11-24

Chief Legal Officer

Transactions

Exercise/Conversion
Common Stock
2025-11-24$6.10/sh+25,000$152,500→ 532,710 total
Exercise/Conversion
Common Stock
2025-11-24$5.13/sh+11,000$56,430→ 543,710 total
Sale
Common Stock
2025-11-24$10.06/sh−36,000$362,268→ 507,710 total
Exercise/Conversion
Common Stock
2025-11-25$5.13/sh+36,000$184,680→ 543,710 total
Sale
Common Stock
2025-11-25$10.00/sh−36,000$360,000→ 507,710 total
Exercise/Conversion
Common Stock
2025-11-26$5.13/sh+23,621$121,176→ 531,331 total
Sale
Common Stock
2025-11-26$10.00/sh−23,621$236,210→ 507,710 total
Exercise/Conversion
Stock Options (right to buy)
2025-11-24−25,000→ 0 total
Exercise: $6.10Exp: 2026-06-15→ Common Stock (25,000 underlying)
Exercise/Conversion
Stock Options (right to buy)
2025-11-24−11,000→ 59,621 total
Exercise: $5.13Exp: 2027-01-03→ Common Stock (11,000 underlying)
Exercise/Conversion
Stock Options (right to buy)
2025-11-25−36,000→ 23,621 total
Exercise: $5.13Exp: 2027-01-03→ Common Stock (36,000 underlying)
Exercise/Conversion
Stock Options (right to buy)
2025-11-26−23,621→ 0 total
Exercise: $5.13Exp: 2027-01-03→ Common Stock (23,621 underlying)

Holdings

Footnotes (2)

[F1]This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.00 to $10.31 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F2]All of the options were fully vested and exercisable as of the transaction date.

Documents

1 file